LUMIRACOXIB
Total Payments
$91,525
Transactions
3
Doctors
0
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $84,427 | 2 | 0 |
| 2017 | $7,098 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $91,525 | 3 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| FIRST IN MAN POC IN PTS WITH RETINITIS PIGMENTOSA | NOVARTIS PHARMACEUTICALS CORPORATION | $58,012 | 0 |
| A MULTI CENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CSJ148 COMPARED TO PLACEBO TO PREVENT HUMAN CYTOMEGALOVIRUS HCMV REPLICATION IN STEM CELL TRANSPLANT PATIENTS | Novartis Pharmaceuticals Corporation | $33,513 | 0 |
Top Doctors Receiving Payments for LUMIRACOXIB
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | San Francisco, CA | $91,525 | 3 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $91,525
- Total Doctors 0
- Transactions 3
About LUMIRACOXIB
LUMIRACOXIB is a drug associated with $91,525 in payments to 0 healthcare providers, recorded across 3 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2018. In 2018, $84,427 was paid across 2 transactions to 0 doctors.
The most common payment nature for LUMIRACOXIB is "Unspecified" ($91,525, 100.0% of total).
LUMIRACOXIB is associated with 2 research studies, including "FIRST IN MAN POC IN PTS WITH RETINITIS PIGMENTOSA" ($58,012).